Sun Pharmaceutical licenses Takeda's gastrointestinal drug Vonoprazan in India, marketing it as Voltapraz.
Sun Pharmaceutical Industries signs a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company to commercialize Takeda's gastrointestinal drug, Vonoprazan, in India. The drug, approved for treatment of adults with Reflux esophagitis and other acid peptic disorders, is an orally active potassium competitive acid blocker. Sun Pharma will market the drug under the brand name Voltapraz in India.
June 21, 2024
3 Articles